# Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer

> **NCT00994864** · NA · COMPLETED · sponsor: **Jules Bordet Institute** · enrollment: 235 (actual)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT00994864
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994864, "Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00994864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*